-
Tytuł:
-
Personality dimensions of patients can change during the course of parkinson's disease.
-
Autorzy:
-
Boussac M; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.
Arbus C; Psychiatry Department of the University Hospital of Toulouse, CHU Purpan, Toulouse, France.
Dupouy J; Department of Neurology, Hospital of Avignon, Avignon, France.
Harroch E; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
Rousseau V; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
Croiset A; CERPPS-Study and Research Center in Psychopathology and Health Psychology, University of Toulouse II Jean-Jaurès, Toulouse, France.
Ory-Magne F; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
Rascol O; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
Moreau C; Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.
Rolland AS; Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.
Maltête D; Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.; Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, INSERM U1239, NS-PARK/FCRIN Network, Mont-Saint-Aignan, France.
Rouaud T; Clinique Neurologique, Hôpital Guillaume et René Laennec, NS-PARK/FCRIN Network, Boulevard Jacques Monod, Nantes, France.
Meyer M; Neurology Department, Nancy University Hospital, Nancy, France.
Drapier S; Behavior and Basal Ganglia Research Unit (EA 4712), University of Rennes 1, Rennes, France.; Department of Neurology, Rennes University Hospital, NS-PARK/FCRIN Network, Rennes, France.
Giordana B; Service Universitaire de Psychiatrie, Hôpital Pasteur 1, CHU de Nice, Nice, France.
Anheim M; Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.; Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, NS-PARK/FCRIN Network, Strasbourg, France.
Hainque E; Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, NS-PARK/FCRIN Network, Paris, France.
Jarraya B; Pôle Neurosciences, Foch Hospital, Suresnes, France.; Université de Versailles Paris-Saclay, INSERM U992, CEA Neurospin, France.
Benatru I; Service de Neurologie, Centre Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, NS-PARK/FCRIN Network, Poitiers, France.
Auzou N; CHU de Bordeaux, Centre Expert Parkinson, Institut des maladies neuro-dégénératives, Bordeaux, France.
Belamri L; Hôpital Fondation A de Rothschild, Service de recherche clinique, Paris, France.
Tir M; Department of Neurology, Department of Neurosurgery, Expert Centre for Parkinson's disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), NS-PARK/FCRIN Network, Amiens, France.
Marques AR; Neurology Department, Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, NS-PARK/FCRIN Network, Clermont-Ferrand, France.
Thobois S; Univ Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Sud Charles Mérieux, Lyon, France.; CNRS, Institut des Sciences Cognitives, UMR 5229, Bron, France.; Centre Expert Parkinson, Hôpital Neurologique 'Pierre Wertheimer', Hospices Civils de Lyon, NS-PARK/FCRIN Network, Lyon, France.
Eusebio A; Aix Marseille Université, AP-HM, Hôpital de La Timone, Service de Neurologie et Pathologie du Mouvement, and UMR CNRS 7289, Institut de Neuroscience de La Timone, NS-PARK/FCRIN Network, Marseille, France.
Corvol JC; Département de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, Inserm U 1127, and CNRS UMR 7225, and Institut du Cerveau et de la Moëlle épinière, NS-PARK/FCRIN Network, Paris, France.
Devos D; Department of Medical Pharmacology, Neurology and Movement Disorders Department, Referent Center of Parkinson's disease, CHU of Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, Licend, NS-PARK/FCRIN Network, Lille, France.
Brefel-Courbon C; Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, Toulouse, France.; Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Center, NS-PARK/FCRIN Network, Toulouse, France.
-
Corporate Authors:
-
PREDI-STIM study group
-
Źródło:
-
PloS one [PLoS One] 2021 Jan 07; Vol. 16 (1), pp. e0245142. Date of Electronic Publication: 2021 Jan 07 (Print Publication: 2021).
-
Typ publikacji:
-
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: San Francisco, CA : Public Library of Science
-
MeSH Terms:
-
Character*
Parkinson Disease/*psychology
Personality Disorders/*psychology
Aged ; Female ; Humans ; Male ; Middle Aged ; Personality Inventory
-
References:
-
J Neurol. 2010 Nov;257(Suppl 2):S276-83. (PMID: 21080189)
Mov Disord. 2016 Aug;31(8):1103-13. (PMID: 27041545)
Neurobiol Stress. 2015 Jan 1;1:164-173. (PMID: 25580450)
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211. (PMID: 12498954)
Mov Disord. 2009 Aug 15;24(11):1561-70. (PMID: 19526584)
J Parkinsons Dis. 2020;10(3):1057-1066. (PMID: 32444557)
Parkinsonism Relat Disord. 2018 Apr;49:67-74. (PMID: 29358028)
Psychiatry Res. 2000 Apr 24;94(1):67-76. (PMID: 10788679)
Brain. 2009 Sep;132(Pt 9):2385-95. (PMID: 19416950)
Eur J Neurosci. 2017 Jan;45(1):67-72. (PMID: 27623191)
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13272-7. (PMID: 11687621)
Psychiatr Genet. 1998 Summer;8(2):41-4. (PMID: 9686420)
Biol Psychol. 1999 Oct;51(1):77-81. (PMID: 10579422)
PeerJ. 2019 Oct 24;7:e7958. (PMID: 31660279)
Biol Psychiatry. 1997 Aug 15;42(4):275-81. (PMID: 9270904)
Psychiatr Genet. 2005 Jun;15(2):145-7. (PMID: 15900230)
Nat Genet. 1996 Jan;12(1):81-4. (PMID: 8528258)
Nat Genet. 1996 Jan;12(1):78-80. (PMID: 8528256)
Arch Gen Psychiatry. 1993 Dec;50(12):975-90. (PMID: 8250684)
Arch Neurol. 2006 Jul;63(7):969-73. (PMID: 16831966)
J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1060-1064. (PMID: 29018160)
Neurology. 2009 May 26;72(21 Suppl 4):S1-136. (PMID: 19470958)
Psychiatry Res. 1996 Nov 1;65(1):61-4. (PMID: 8953662)
J Neurol. 2016 Sep;263(9):1828-39. (PMID: 27334907)
Am J Med Genet. 1998 May 8;81(3):257-67. (PMID: 9603615)
-
Molecular Sequence:
-
ClinicalTrials.gov NCT02360683
-
Entry Date(s):
-
Date Created: 20210107 Date Completed: 20210510 Latest Revision: 20231110
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC7790271
-
DOI:
-
10.1371/journal.pone.0245142
-
PMID:
-
33411732
-
Background: Studies assessing personality dimensions by the "Temperament and Character Inventory" (TCI) have previously found an association between Parkinson's disease (PD) and lower Novelty Seeking and higher Harm Avoidance scores. Here, we aimed to describe personality dimensions of PD patients with motor fluctuations and compare them to a normative population and other PD populations.
Methods: All PD patients awaiting Deep Brain Stimulation (DBS) answered the TCI before neurosurgery. Their results were compared to those of historical cohorts (a French normative population, a de novo PD population, and a PD population with motor fluctuations).
Results: Most personality dimensions of our 333 included PD patients with motor fluctuations who are candidates for DBS were different from those of the normative population and some were also different from those of the De Novo PD population, whereas they were similar to those of another population of PD patients with motor fluctuations.
Conclusions: During the course of PD, personality dimensions can change in parallel with the development of motor fluctuations, either due to the evolution of the disease and/or dopaminergic treatments.
Competing Interests: The authors have declared that no competing interests exist.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
